ALYGLO™ is a safe, effective, and extra-purified 10% liquid intravenous immune globulin (IVIG) treatment.1
A longstanding goal within the immunoglobulin (IG) industry has been to remove coagulation factor XIa (FXIa), a plasma-based enzyme linked to IVIG-related thromboembolic events.2
ALYGLO is manufactured with cation exchange (CEX) chromatography, which is proven to reduce FXIa to undetectable levels.2
As a top global manufacturer of plasma therapeutics, we have been delivering safe and effective therapies to patients for more than 50 years.
As we enter the United States, our mission is to accelerate the development and delivery of therapies for patients in need of treatment.
We are also working to help address challenges associated with IVIG.
aStudy design: Efficacy, safety, and tolerability of ALYGLO were evaluated in a prospective, open-label study of 33 adults aged 17-70 years.1 See the full clinical study design.
bClick here to see terms, conditions, and eligibility criteria.
References:
ALYGLO™ is indicated for the treatment of primary humoral immunodeficiency (PI) in adults aged 17 years and older. This includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
WARNING: THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE
Thrombosis may occur with immune globulin intravenous (IGIV) products, including ALYGLO. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.
Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur with the administration of IGIV products in predisposed patients.
Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. ALYGLO does not contain sucrose.
For patients at risk of thrombosis, renal dysfunction or renal failure, administer ALYGLO at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
For more information about ALYGLO, please see full Prescribing Information.